Abstract
Adjuvant therapy represents the gold standard treatment for radically resected pancreatic cancer. Results from randomized clinical trials confirmed the efficacy of adjuvant therapy for pancreatic cancer but did not define what is the "right choice" in terms of type of antiblastic drug (among gemcitabine, 5-fluorouracil or other drugs), role of polychemotherapy and chemoradiotherapy. The objective of our study was to evaluate the efficacy and toxicity of adjuvant chemotherapy and chemoradiotherapy for radically resected pancreatic cancer through a systematic review of literature data, emphasizing the benefits regarding overall survival, disease-free survival and toxicity.
Publication types
-
Comparative Study
-
Review
-
Systematic Review
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chemoradiotherapy
-
Chemotherapy, Adjuvant / adverse effects
-
Chemotherapy, Adjuvant / methods
-
Clinical Trials, Phase II as Topic / statistics & numerical data
-
Clinical Trials, Phase III as Topic / statistics & numerical data
-
Combined Modality Therapy
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Gemcitabine
-
Humans
-
Mitomycin / administration & dosage
-
Multicenter Studies as Topic / statistics & numerical data
-
Pancreatectomy / methods*
-
Pancreatic Neoplasms / drug therapy
-
Pancreatic Neoplasms / radiotherapy
-
Pancreatic Neoplasms / surgery*
-
Pancreatic Neoplasms / therapy
-
Practice Guidelines as Topic
-
Radiotherapy, Adjuvant / adverse effects
-
Randomized Controlled Trials as Topic / statistics & numerical data
-
Survival Analysis
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Mitomycin
-
Doxorubicin
-
Fluorouracil
-
Gemcitabine